All Stories

  1. In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases
  2. Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases
  3. Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
  4. Activated ClpP kills persisters and eradicates a chronic biofilm infection
  5. In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
  6. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
  7. Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor
  8. Extending the life of β-lactam antibiotics: New β-lactamase inhibitors
  9. Recent advances in the treatment of Gram-positive infections
  10. Effect of extended pre-incubation with chlamydia pneumoniae and extended incubation with antimicrobial on the minimum inhibitory concentrations (MICs) of five antimicrobials
  11. Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro
  12. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens
  13. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA
  14. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae
  15. Rapid detection of antimicrobial activity using flow cytometry
  16. Section Review: Anti-infectives: An update on β-lactamases and β-lactamase inhibitors
  17. The application of flow cytometry to the estimation of bacterial antibiotic susceptibility
  18. Bacterial resistance mechanisms as therapeutic targets
  19. Characterization of Bacterial Cell Size and Ploidy using Flow Cytometry and Image Analysis
  20. Pharmacokinetic studies and renal dehydropeptidase stability of the new beta-lactamase inhibitor BRL 42715 in animals.
  21. The automated in-vitro assesment of β-lactamase inhibitors
  22. 6-(Substituted methylene)penems, potent broad spectrum inhibitors of bacterial .BETA.-lactamase. V. Chiral 1,2,3-triazolyl derivatives.
  23. 6-(Substituted methylene)penems, potent broad spectrum inhibitors of bacterial .BETA.-lactamase. III. Structure-activity relationships of the 5-membered heterocyclic derivatives.
  24. 6-(Substituted methylene)penems, potent broad spectrum inhibitors of bacterial .BETA.-lactamase. IV. Kidney stability, serum binding and additional biological evaluation of racemic derivatives.
  25. 6-(Substituted methylene)penems, potent broad spectrum inhibitors of bacterial .BETA.-lactamase. II. Racemic furyl and thienyl derivatives.
  26. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.
  27. Synthesis and .BETA.-lactamase inhibitory activity of 9-(2-amidoethenylthio)-9-deoxy derivatives of clavulanic acid.
  28. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin
  29. Antimicrobial substances and chick growth promotion: Comparative studies on selected compoundsin vitroandin vivo
  30. Antimicrobial substances and chick growth promotion: The growth‐promoting activities of antimicrobial substances, including fifty‐two used either in therapy or as dietary additives